4'-乙炔基-2'-氟-2'-脱氧腺苷、替诺福韦艾拉酚胺及第二代NNRTIs对不同HIV-1亚型的抗逆转录病毒效力
研究比较了EFdA与替诺福韦艾拉酚胺、奈韦拉平、依非韦伦、利匹韦林和依曲韦林对多种HIV-1亚型嵌合病毒及耐药株的抑制效力。结果显示EFdA对治疗初治患者嵌合病毒的EC50中位数为1.4 nM,与替诺福韦艾拉酚胺的1.6 nM相当;依曲韦林和利匹韦林存在亚型特异性差异,HIV-1C的EC50最高。EFdA对耐药株效力更高,且抑制具有亚型非依赖性。
要点
- EFdA对治疗初治患者嵌合病毒的EC50中位数为1.4 nM,与替诺福韦艾拉酚胺的1.6 nM相当。
- 依曲韦林(P=0.004)和利匹韦林(P=0.017)存在亚型特异性差异,HIV-1C的EC50最高。
- EFdA对逆转录酶抑制剂耐药株效力更高,且抑制具有亚型非依赖性。
核心结论
- 病毒学和生化数据提示EFdA以亚型非依赖方式有效抑制野生型和逆转录酶抑制剂耐药病毒。
- HIV-1C对依曲韦林和利匹韦林最不敏感。
研究设计与样本
- 使用编码治疗初治患者(n=24)和治療失败患者(n=3)gag-pol的pNL4.3嵌合病毒及一组逆转录酶抑制剂耐药株(n=7)比较逆转录酶抑制剂药物的效力。
- 表型药物敏感性试验使用TZM-bl细胞进行,体外抑制试验使用患者来源逆转录酶,NNRTIs的IC50值使用基于PicoGreen的分光光度法计算。
- 稳态动力学用于测定EFdA三磷酸形式(EFdA-TP)和dATP的表观结合亲和力(Km.dNTP)。
主要发现
- 在治疗初治患者嵌合病毒中,EFdA的体外抗逆转录病毒活性[中位数(IQR)EC50=1.4 nM(0.6-2.1 nM)]与替诺福韦艾拉酚胺[1.6 nM(0.5-3.6 nM)]相当。
- 依曲韦林(P=0.004)和利匹韦林(P=0.017)存在亚型特异性差异,HIV-1C的EC50值最高。
- EFdA相对于天然底物dATP具有更高的比较效率,倍数变化在1.6至3.2之间。
- 对逆转录酶抑制剂耐药株的体外分析显示EFdA具有更高的效力。
- 尽管存在利匹韦林耐药突变,一些非B亚型株对利匹韦林表现出超敏感。
关键数值与推荐
- EFdA对治疗初治患者嵌合病毒的EC50中位数为1.4 nM(IQR 0.6-2.1 nM),替诺福韦艾拉酚胺为1.6 nM(IQR 0.5-3.6 nM)。
- 依曲韦林亚型差异P=0.004,利匹韦林亚型差异P=0.017,HIV-1C的EC50值最高。
- EFdA-MP掺入效率相对于dATP掺入效率的倍数变化在1.6至3.2之间。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: 4'-Ethnyl-2'-fluoro-2'-deoxyadenosine (EFdA) is a novel translocation-defective reverse transcriptase inhibitor. We investigated the virological and biochemical inhibitory potentials of EFdA against a broad spectrum of subtype-specific chimeric viruses and compared it with tenofovir alafenamide, nevirapine, efavirenz, rilpivirine and etravirine. METHODS: pNL4.3 chimeric viruses encoding gag-pol from treatment-naive patients (n = 24) and therapy-failure patients (n = 3) and a panel of reverse transcriptase inhibitor-resistant strains (n = 7) were used to compare the potency of reverse transcriptase inhibitor drugs. The phenotypic drug susceptibility assay was performed using TZM-bl cells. In vitro inhibition assays were done using patient-derived reverse transcriptase. IC50 values of NNRTIs were calculated using a PicoGreen-based spectrophotometric assay. Steady-state kinetics were used to determine the apparent binding affinity (Km.dNTP) of triphosphate form of EFdA (EFdA-TP) and dATP. RESULTS: Among the chimeric treatment-naive viruses, EFdA had an ex vivo antiretroviral activity [median (IQR) EC50 = 1.4 nM (0.6-2.1 nM)] comparable to that of tenofovir alafenamide [1.6 nM (0.5-3.6 nM)]. Subtype-specific differences were found for etravirine (P = 0.004) and rilpivirine (P = 0.017), where HIV-1C had the highest EC50 values. EFdA had a greater comparative efficiency [calculated by dividing the efficiency of monophosphate form of EFdA (EFdA-MP) incorporation (kcat.EFdA-TP/Km.EFdA-TP) over the efficiency of dATP incorporation (kcat.dATP/Km.dATP)] compared with the natural substrate dATP, with a fold change of between 1.6 and 3.2. Ex vivo analysis on reverse transcriptase inhibitor-resistant strains showed EFdA to have a higher potency. Despite the presence of rilpivirine DRMs, some non-B strains showed hypersusceptibility to rilpivirine. CONCLUSIONS: Our combined virological and biochemical data suggest that EFdA inhibits both WT and reverse transcriptase inhibitor-resistant viruses efficiently in a subtype-independent manner. In contrast, HIV-1C is least susceptible to etravirine and rilpivirine.
引用
- Njenda DT, Aralaguppe SG, Singh K, et al. Antiretroviral potency of 4'-ethnyl-2'-fluoro-2'-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes. J Antimicrob Chemother. 2018. PMID: 30053052. doi:10.1093/jac/dky256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。